BRAIN Biotech AGHAM:BNN 69 Forward Dividend Yield % is 0.00% as of Jun. 29, 2026. GuruFocus rates HAM:BNN with a GF Score™ of 69/100 and a GF Value™ of €2.56 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,026 Chemicals companies, BRAIN Biotech AG ranks worse than 97465.79% on this metric.
As of today (2026-06-29), the Forward Annual Dividend Yield of BRAIN Biotech AG is 0.00%.
As of today (2026-06-29), the Trailing Annual Dividend Yield of BRAIN Biotech AG is 0.00%.
HAM:BNN's Forward Dividend Yield % is not ranked *
in the Chemicals industry.
Industry Median: 1.58 * Ranked among companies with meaningful Forward Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
BRAIN Biotech AG (HAM:BNN) Forward Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
BRAIN Biotech AG Forward Dividend Yield % Related Terms
HAM:BNN vs LIN, SHW, ECL: Forward Dividend Yield % Comparison
For the Specialty Chemicals subindustry, BRAIN Biotech AG's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BRAIN Biotech AG Forward Dividend Yield % vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, BRAIN Biotech AG's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where BRAIN Biotech AG's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
BRAIN Biotech AG (HAM:BNN) has a Forward Dividend Yield % of 0.00% as of Jun. 29, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on BRAIN Biotech AG and its competitors. According to the industry distribution chart, BRAIN Biotech AG ranks #999999 out of 1026 companies in the Chemicals industry.
Is BRAIN Biotech AG's Forward Dividend Yield % too high?
BRAIN Biotech AG's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, BRAIN Biotech AG ranks #999999 out of 1026 companies in the Chemicals industry, which is in the bottom quartile relative to peers. Overall, BRAIN Biotech AG has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BRAIN Biotech AG's Forward Dividend Yield % compare to LIN and SHW?
According to the Chemicals industry distribution chart, BRAIN Biotech AG ranks #999999 out of 1026 companies for Forward Dividend Yield %. This places BRAIN Biotech AG in the lower half of its industry. The industry median Forward Dividend Yield % is 1.58. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Chemicals company?
The median Forward Dividend Yield % among Chemicals companies is 1.58, based on 1,026 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on BRAIN Biotech AG and its competitors. For the Chemicals industry, the median Forward Dividend Yield % is 1.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BRAIN Biotech AG's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BRAIN Biotech AG stock overvalued right now?
Based on GuruFocus' analysis, BRAIN Biotech AG (HAM:BNN) is currently considered Fairly Valued. The stock's GF Value™ is €2.56, compared to a current price of €2.82 — trading 10.2% above its estimated fair value. The current Forward Dividend Yield % is 0.00%. BRAIN Biotech AG's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For BRAIN Biotech AG (HAM:BNN), the current Forward Dividend Yield % is 0.00% as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BRAIN Biotech AG (HAM:BNN) Overvalued in 2026?
Based on GuruFocus' analysis, BRAIN Biotech AG stock appears to be overvalued.
The current stock price of €2.82 is trading 10.2% above its estimated GF Value™ of €2.56.
GuruFocus considers BRAIN Biotech AG to be Fairly Valued.
Key valuation signals for HAM:BNN:
Forward Dividend Yield %: 0.00%
GF Value™: €2.56 vs. price of €2.82 (10.2% above fair value)
No single metric tells the full story. See the HAM:BNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BRAIN Biotech AG is an industrial biotechnology specialist focused on enzyme technology, microbial production strains, and bioprocess design to enable bio-based innovations. The Group conducts research, development, and production for client specifications and its own product portfolio, supporting customers in the food and beverage, chemical, and life sciences industries with solutions that enhance productivity, efficiency, and sustainability. Its operations are organized into two segments: BRAIN Biocatalysts, which develops, produces, and distributes specialty enzymes, microorganisms, and ingredients and generates the majority of revenue, and BRAIN BioIncubator, which focuses on development projects. The company operates in Germany and other countries.
69GF Score
Get the complete analysis for HAM:BNN
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:BNN has been successfully added to your 